Skip to content
2000
Volume 2, Issue 8
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Objective: Coronavirus Disease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of Severe Acute Respiratory Syndrome (SARS). Methods: Currently, many drugs/therapies have been tested for COVID-19, which responded sub- -optimally to the patients. Remdesivir is an RNA polymerase inhibitor that found promising results in ongoing clinical trials and shows a faster recovery rate in COVID-19 patients. Currently, USFDA approves for emergent use of this drug in severe COVID-19 patients. Results: In this review, we discussed a brief overview of biopharmaceutical and pharmacological aspects of Remdesivir. Moreover, the ongoing regulatory status of Remdesivir by official bodies has also been described.

Loading

Article metrics loading...

/content/journals/covid/10.2174/2666796701999201218141652
2021-08-01
2025-12-18
Loading full text...

Full text loading...

/content/journals/covid/10.2174/2666796701999201218141652
Loading

  • Article Type:
    Review Article
Keyword(s): COVID-19; Remdesivir; RNA polymerase inhibitor; SARS; USFDA; WHO
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test